Developing Products for Rare Diseases & Conditions

[FDA]

The Orphan Drug Designation program provides orphan status to drugs and biologics which are defined as those intended for the safe and effective treatment, diagnosis or prevention of rare diseases/disorders that affect fewer than 200,000 people in the U.S., or that affect more than 200,000 persons


Baca selengkapnya di : http://www.fda.gov...